期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

ARB在糖尿病患者中的临床应用 被引量：8

下载PDF
导出
摘要 血管紧张素Ⅱ受体拮抗剂（ARB）具有较为平稳的长效降压作用，较低的不良反应发生率和良好的治疗依从性。大量的基础和临床研究已经确立了ARB作为有效抗高血压药物的地位。在糖尿病合并高血压的降压治疗方面，
作者 傅汉菁
机构地区 首都医科大学附属北京同仁医院内分泌科
出处 《药品评价》 CAS 2008年第8期350-354,共5页 Drug Evaluation
关键词 血管紧张素Ⅱ受体拮抗剂 糖尿病 肾病 高血压
分类号 R587.1 [医药卫生—内分泌]
  • 相关文献

参考文献8

  • 1孙宁玲.血管紧张素受体拮抗剂在高血压治疗中的作用及地位[J].中华医学杂志,2005,85(25):1732-1733. 被引量：34
  • 2谌贻璞.ACEI与ARB肾脏保护作用研究进展[J].中国医药导刊,2007,9(2):122-124. 被引量：28
  • 3Lewis EJ;Hunsicker LG;Clarke WR.Collaborative Study Group Renoprotective effect of the angiotension receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes,2001(12).
  • 4Brenner BM;Cooper ME;de Zeeuw D.RENAAL Study lnvestigators Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy,2001(12).
  • 5Parring HH;Lehnert H;Brochner-Mortensen J.The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes,2001(12).
  • 6Julius S,Kjeldsen SE,Weber M,et al.Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine:the VALUE randomised trialThe Lancet,2004.
  • 7Lindholm LH;Ibsen H;Dahlof B.Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study(LIFE):a randomised trial against atenolol,2002(9310).
  • 8Dahlof B;Devereux RB;Kjeldsen SE.Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study(LIFE):a randomised trial against atenolol,2002(9310).

二级参考文献27

  • 1谌贻璞.慢性肾脏病高血压的治疗目标及药物应用[J].临床内科杂志,2005,22(11):726-728. 被引量：26
  • 2Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet, 2004, 363: 2022-2031.
  • 3Hasford J, Mimran A, Simons WR. A population-based european cohort study of persistence in newly diagnosed hypertensive patients. J Hum Hypertens, 2002, 16: 569-575.
  • 4Bloom BS. Continuation of initial antihypertensive medication after 1 year of therapy. Clin Ther, 1998, 20: 671-681.
  • 5Elliott WJ. Cyclic and circadian variations in cardiovascular events. Am J Hypertens, 2001, S291-S295.
  • 6Shimada K, Kawamoto A, Matsubayashi K, et al. Diurnal blood pressure variations and silent cerebrovascular damage in elderly patients with hypertension. J Hypertens, 1992, 10: 875-878.
  • 7Lacourciere Y, Lenis J, R Orchard, et al. A comparison of the efficacies and duration of action of the angiotensin II receptor blockers telmisartan and amlodipine. Blood Press Monit, 1998, 3: 295-302.
  • 8Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC7 report. JAMA, 2003, 289: 2560-2571.
  • 9MacKay JH, Arcuri KE, Goldberg A. I, et al. Losartan and low-dose hydrochlorothiazide in patients with essential hypertension. A double-blind, placebo-controlled trial of concomitant administration compared with individual components. Arch Intern Med, 1996, 156: 278-285.
  • 10Oparil S,Weber MA.Hypertension:A Companion to Brenner and Rector's The Kidney.St.Louis:Saunders,2000; 70 ～ 110

共引文献57

同被引文献55

引证文献8

二级引证文献26

药品评价
2008年 第8期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部